Listing of claims

Please amend claims 8, 46-49, 60, and 66 as shown below.

Please also add new claims 76-81.

1-7 (canceled).

8. (currently amended) The stent of claim 46 comprising:

a radially self-expanding tubular shaped member having first and second ends; a walled surface disposed between said first and second ends;

said walled surface comprising a plurality of substantially parallel pairs of monofilaments; said substantially parallel pairs of monofilaments woven in a helical shape such that substantially one-half of said substantially parallel pairs of monofilaments are wound clockwise in the longitudinal direction and one-half of said substantially parallel pairs of monofilaments are wound counterclockwise in the longitudinal direction such that an alternating, over-under plait of said substantially parallel pairs of monofilaments results; said monofilaments ~~comprising a~~ consisting essentially of the blend of ~~at least~~ two bioresorbable, bio-compatible homopolymers.

9. (previously presented) The stent of claim 8, comprising approximately twenty-four substantially parallel pairs of monofilaments.

10. (previously presented) The stent of claim 8, wherein said bioresorbable, bio-compatible homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

11. (previously presented) The stent of claim 8, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

12. (previously presented) The stent of claim 8, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi to 2,000,000 psi.

13. (previously presented) The bioresorbable stent of claim 8, wherein said stent has a compressed first diameter of between approximately 6 mm and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

14. (previously presented) The bioresorbable stent of claim 8 wherein said woven monofilaments have a crossing angle of between approximately 100 degrees and 150 degrees in the non-compressed resting state.

15-45 (canceled).

46. (currently amended) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member ~~comprising~~ consisting essentially of a blend of ~~at least~~ two bioresorbable, bio-compatible homopolymers, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.

47. (currently amended) The stent of claim 46 comprising:

~~a tubular-shaped member having first and second ends;~~

a walled surface disposed between said first and second ends;

said walled surface comprising a helical shape of woven monofilaments ~~comprising a~~ consisting essentially of the blend of ~~at least~~ two bioresorbable, bio-compatible homopolymers.

48. (currently amended) The stent of claim 47, wherein the two ~~said blend of~~ bioresorbable, bio-compatible polymers ~~is~~ are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

49. (currently amended) The stent of claim 47, wherein said walled ~~structure~~ surface has approximately 30 monofilaments.

50. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

51. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi to 2,000,000 psi.

52. (previously presented) The stent of claim 47, wherein said stent has a compressed first diameter of between approximately 6 mm and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

53. (previously presented) The stent of claim 47, wherein said woven monofilaments have a crossing angle of between approximately 100 degrees and 150 degrees in the non-compressed resting state.

54. (withdrawn) The stent of claim 46, wherein the stent comprises a substantially tubular shaped device;

said tubular shape device having a first and second ends;

a walled structure disposed between said first and second ends;

said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

55. (withdrawn) The stent of claim 54, wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

56. (withdrawn) The stent of claim 54, wherein said polymer blend possesses a tensile strength in the range of approximately 8,000 psi to 12,000 psi.

57. (withdrawn) The stent of claim 54, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi to 800,000 psi.

58. (withdrawn) The stent of claim 54, wherein said stent has a compressed first diameter of between approximately 6 mm and 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

59. (previously presented) The stent of claim 46, wherein the stent is a urethral stent.

60. (currently amended) The stent of claim 46, wherein the ~~stent comprises a blend of~~ two homopolymers are present in a ratio of between approximately 50:50 and 70:30.

61. (withdrawn) A bioresorbable, self-expanding stent comprising,
wherein the stent comprises a substantially tubular shaped device;
said tubular shape device having a first and second ends;
a walled structure disposed between said first and second ends;
said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

62. (withdrawn) The stent of claim 61 wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

63. (withdrawn) The stent of claim 61 wherein said stent has a compressed first diameter of between approximately 6 millimeter ~~to~~ and 10 millimeter and a second non-compressed diameter of between approximately 12 millimeter and 18 millimeter.

64. (withdrawn) The stent of claim 61 wherein the stent is a urethral stent.

65. (withdrawn) The stent of claim 61 wherein the stent comprises a blend of homopolymers in a ratio of between approximately 50:50 and 70:30.

66. (currently amended) The stent of claim 10~~, wherein said polymers are~~ consisting essentially of poly-L-lactide and poly-ε-caprolactone.

67. (previously presented) The stent of claim 66, wherein poly-L-lactide and poly-ε-caprolactone are present at a ratio between approximately 80:20 and 99:1.

68. (previously presented) The stent of claim 67, wherein the ratio is approximately 90:10.

69. (previously presented) The stent of claim 66 wherein the poly-L-lactide has a molecular weight of approximately 450,000 daltons or greater.

70. (previously presented) The stent of claim 69 wherein the poly-L-lactide has a molecular weight of approximately 750,000 daltons or greater.

71. (previously presented) The stent of claim 66 wherein the poly-ε-caprolactone has a molecular weight of approximately 100,000 daltons or greater.

72. (previously presented) The stent of claim 71 wherein the poly-ε-caprolactone has a molecular weight of approximately 200,000 daltons or greater.

73. (withdrawn) The stent of claim 62, wherein said polymers are poly-L-lactide and poly-D-L-lactide.

74. (withdrawn) The stent of claim 73 wherein the poly-D-L-lactide has a molecular weight of approximately 100,000 daltons or greater.

75. (withdrawn) The stent of claim 74 wherein the poly-D-L-lactide has a molecular weight of approximately 500,000 daltons or greater.

76. (new) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising a blend of at least two bioresorbable, bio-compatible homopolymers present in a ratio of between approximately 50:50 and 70:30, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.

77. (new) The stent of claim 76, wherein said two bioresorbable, bio-compatible homopolymers are selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly-ε-caprolactone.

78. (new) The stent of claim 77, wherein said two bioresorbable, bio-compatible homopolymers are poly-L-lactide and poly-D-L-lactide.

79. (new) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising poly-L-lactide and poly-ε-caprolactone homopolymers, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.

80. (new) The stent of claim 79, wherein poly-L-lactide and poly-ε-caprolactone are present at a ratio between approximately 80:20 and 99:1.

81. (new) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising a blend of at least two bioresorbable, bio-compatible homopolymers, wherein one of the two homopolymers is poly-ε-caprolactone having a molecular weight of approximately 200,000 daltons or greater, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.